Advisors Preferred LLC Buys New Position in Stryker Corporation $SYK

Key Points

• Advisors Preferred LLC acquired 4,300 Stryker shares worth approximately $1.4 million in the second quarter, joining several other institutions that initiated positions. Institutional investors and hedge funds collectively own 77.09% of Stryker.
• Stryker reported quarterly EPS of $3.69, exceeding analysts’ $3.49 estimate, while revenue rose 9.4% year over year to $6.59 billion. The company issued fiscal 2026 EPS guidance of $14.95–$15.10.
• The stock opened at $327.97, down 3.5%, while analysts maintained a generally positive outlook with a “Moderate Buy” consensus and an average price target of $386.28. Stryker also declared a quarterly dividend of $0.88 per share, yielding approximately 1.1% annually.

Advisors Preferred LLC acquired a new stake in shares of Stryker Corporation (NYSE:SYK - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 4,300 shares of the medical technology company's stock, valued at approximately $1,404,000.

A number of other hedge funds have also recently bought and sold shares of SYK. Fairtree Asset Management Pty Ltd acquired a new position in Stryker in the second quarter valued at $2,379,000. Oxford Financial Group LTD. LLC purchased a new position in shares of Stryker in the 2nd quarter worth about $713,000. Kilter Group LLC purchased a new position in shares of Stryker in the 2nd quarter worth about $25,000. D L Carlson Investment Group Inc. acquired a new position in shares of Stryker in the 2nd quarter valued at about $3,089,000. Finally, Portfolio Design Labs LLC purchased a new stake in shares of Stryker during the 2nd quarter worth about $1,348,000. Institutional investors and hedge funds own 77.09% of the company's stock.

Stryker Stock Down 3.5%

Shares of Stryker stock opened at $327.97 on Friday. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59. The business's 50 day simple moving average is $326.64 and its 200-day simple moving average is $332.66. The stock has a market capitalization of $125.80 billion, a price-to-earnings ratio of 33.99, a PEG ratio of 2.17 and a beta of 0.76. Stryker Corporation has a twelve month low of $281.00 and a twelve month high of $396.86.

Stryker (NYSE:SYK - Get Free Report) last posted its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The firm had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.58 billion. During the same period in the previous year, the business posted $3.13 EPS. Stryker's revenue was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities research analysts forecast that Stryker Corporation will post 15.02 earnings per share for the current year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 annualized dividend and a yield of 1.1%. Stryker's dividend payout ratio (DPR) is currently 36.48%.

Insider Buying and Selling

In other news, Director Ronda E. Stryker sold 310,000 shares of the business's stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the sale, the director directly owned 1,924,880 shares of the company's stock, valued at $601,005,282.40. The trade was a 13.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Debra King sold 826 shares of the company's stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total transaction of $277,783.80. Following the sale, the insider directly owned 6,210 shares of the company's stock, valued at $2,088,423. This represents a 11.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 665,370 shares of company stock valued at $216,238,501 over the last three months. Company insiders own 4.60% of the company's stock.

Analysts Set New Price Targets

Several research firms have recently issued reports on SYK. Piper Sandler dropped their price objective on shares of Stryker from $420.00 to $390.00 and set an "overweight" rating for the company in a research report on Friday, July 31st. Evercore set a $350.00 target price on shares of Stryker in a report on Monday, July 6th. BTIG Research lowered their price target on Stryker from $371.00 to $358.00 and set a "buy" rating for the company in a report on Friday, July 31st. The Goldman Sachs Group reissued a "neutral" rating and issued a $361.00 price objective on shares of Stryker in a research report on Friday, May 1st. Finally, Wolfe Research cut Stryker from an "outperform" rating to a "peer perform" rating in a research note on Thursday, August 13th. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $386.28.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source